146 related articles for article (PubMed ID: 27174050)
1. Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes.
Chow MJ; Babak MV; Wong DY; Pastorin G; Gaiddon C; Ang WH
Mol Pharm; 2016 Jul; 13(7):2543-54. PubMed ID: 27174050
[TBL] [Abstract][Full Text] [Related]
2. Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.
Chow MJ; Licona C; Yuan Qiang Wong D; Pastorin G; Gaiddon C; Ang WH
J Med Chem; 2014 Jul; 57(14):6043-59. PubMed ID: 25023617
[TBL] [Abstract][Full Text] [Related]
3. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
4. Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes.
Chow MJ; Babak MV; Tan KW; Cheong MC; Pastorin G; Gaiddon C; Ang WH
Mol Pharm; 2018 Aug; 15(8):3020-3031. PubMed ID: 29979603
[TBL] [Abstract][Full Text] [Related]
5. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Palepu NR; Nongbri SL; Premkumar JR; Verma AK; Bhattacharjee K; Joshi SR; Forbes S; Mozharivskyj Y; Thounaojam R; Aguan K; Kollipara MR
J Biol Inorg Chem; 2015 Jun; 20(4):619-38. PubMed ID: 25712889
[TBL] [Abstract][Full Text] [Related]
7. Tuning the cytotoxic properties of new ruthenium(III) and ruthenium(II) complexes with a modified bis(arylimino)pyridine Schiff base ligand using bidentate pyridine-based ligands.
Garza-Ortiz A; Maheswari PU; Lutz M; Siegler MA; Reedijk J
J Biol Inorg Chem; 2014 Jun; 19(4-5):675-89. PubMed ID: 24430199
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium(II) carbonyl complexes containing S-methylisothiosemicarbazone based tetradentate ligand: synthesis, characterization and biological applications.
Selvamurugan S; Ramachandran R; Viswanathamurthi P
Biometals; 2013 Oct; 26(5):741-53. PubMed ID: 23780567
[TBL] [Abstract][Full Text] [Related]
9. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
10. Microwave-assisted synthesis of arene ruthenium(II) complexes that induce S-phase arrest in cancer cells by DNA damage-mediated p53 phosphorylation.
Wu Q; Fan C; Chen T; Liu C; Mei W; Chen S; Wang B; Chen Y; Zheng W
Eur J Med Chem; 2013 May; 63():57-63. PubMed ID: 23455057
[TBL] [Abstract][Full Text] [Related]
11. Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium(II) arene complex with considerable in vitro cytotoxicity against cancer cells and a lower in vivo toxicity in zebrafish embryos than clinically approved cis-platin.
Haghdoost M; Golbaghi G; Létourneau M; Patten SA; Castonguay A
Eur J Med Chem; 2017 May; 132():282-293. PubMed ID: 28371640
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
13. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
14. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
15. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
Wang Z; Qian H; Yiu SM; Sun J; Zhu G
J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
[TBL] [Abstract][Full Text] [Related]
16. Selective cytotoxic Ru(II) arene Cp* complex salts [R-PhRuCp*](+)X(-) for X = BF4(-), PF6(-), and BPh4(-).
Loughrey BT; Healy PC; Parsons PG; Williams ML
Inorg Chem; 2008 Oct; 47(19):8589-91. PubMed ID: 18783214
[TBL] [Abstract][Full Text] [Related]
17. Copper complexes based on chiral Schiff-base ligands: DNA/BSA binding ability, DNA cleavage activity, cytotoxicity and mechanism of apoptosis.
Zhou XQ; Li Y; Zhang DY; Nie Y; Li ZJ; Gu W; Liu X; Tian JL; Yan SP
Eur J Med Chem; 2016 May; 114():244-56. PubMed ID: 26994692
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells.
Allison SJ; Cooke D; Davidson FS; Elliott PIP; Faulkner RA; Griffiths HBS; Harper OJ; Hussain O; Owen-Lynch PJ; Phillips RM; Rice CR; Shepherd SL; Wheelhouse RT
Angew Chem Int Ed Engl; 2018 Jul; 57(31):9799-9804. PubMed ID: 29863754
[TBL] [Abstract][Full Text] [Related]
19. Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents.
Vajpayee V; Yang YJ; Kang SC; Kim H; Kim IS; Wang M; Stang PJ; Chi KW
Chem Commun (Camb); 2011 May; 47(18):5184-6. PubMed ID: 21451846
[TBL] [Abstract][Full Text] [Related]
20. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.
Yan YK; Melchart M; Habtemariam A; Sadler PJ
Chem Commun (Camb); 2005 Oct; (38):4764-76. PubMed ID: 16193110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
